You must subscribe to access archives older than one year.
Take a free trial of
Briefing In Play® now.
TERMS OF USE
The Briefing.com RSS (really simple syndication) service
is a method by which we offer story headline feeds in XML format
to readers of the Briefing.com web site who use RSS aggregators.
By using Briefing.com’s RSS service you agree to be bound by
these Terms of Use. If you do not agree to the terms and conditions
contained in these Terms of Use, we do not consent to provide
you with an RSS feed and you should not make use of Briefing.com’s
RSS service. The use of the RSS service is also subject to the
terms and conditions of the
Briefing.com Reader Agreement which governs the use
of Briefing.com's entire web site (www.briefing.com)
including all information services. These Terms of Use and the
Briefing.com Reader Agreement may be changed by Briefing.com
at any time without notice.
Use of RSS Feeds:
The Briefing.com RSS service is provided free of charge for
use by individuals, as long as the feeds are used for such individual’s
personal, non-commercial use. Any other uses, including without
limitation the incorporation of advertising into or the placement
of advertising associated with or targeted towards the RSS Content,
are strictly prohibited. You are required to use the RSS feeds
as provided by Briefing.com and you may not edit or modify the
text, content or links supplied by Briefing.com. To acquire
more extensive licensing rights to Briefing.com content please
review this page.
Link to Content Pages:
The RSS service may be used only with those platforms from which
a functional link is made available that, when accessed, takes
the viewer directly to the display of the full article on the
Briefing.com web site. You may not display the RSS content in
a manner that does not permit successful linking to, redirection
to or delivery of the applicable Briefing.com web site page.
You may not insert any intermediate page, “splash” page or any
other content between the RSS link and the applicable Briefing.com
web site page.
Ownership/Attribution:
Briefing.com retains all ownership and other rights in the RSS
content, and any and all Briefing.com logos and trademarks used
in connection with the RSS service. You are required to provide
appropriate attribution to the Briefing.com web site in connection
with your use of the RSS feeds. If you provide this attribution
using a graphic we require you to use the Briefing.com web site
logo that we have incorporated into the Briefing.com RSS feed.
Right to Discontinue Feeds:
Briefing.com reserves the right to discontinue providing any
or all of the RSS feeds at any time and to require you to cease
displaying, distributing or otherwise using any or all of the
RSS feeds for any reason including, without limitation, your
violation of any provision of these Terms of Use or the terms
and conditions of the Briefing.com Reader Agreement. Briefing.com
assumes no liability for any of your activities in connection
with the RSS feeds or for your use of the RSS feeds in connection
with your web site.
Centene shares fall 4% following disappointing guidance
Centene (CNC $43.15 -1.82) issued guidance for fiscal year 2012 with EPS of $0.10-0.20, does not appear comparable to $1.50 Capital IQ consensus, but lower than co's prior guidance $0.56-0.66. The company issued guidance for fiscal year 2013 with EPS of $2.60-2.90 versus the $2.82 consensus and revenues of fiscal year 2013 Premium and Service revenues of $9.7-10.0 billion, may not be comparable to $10.17 bln (consolidated) Capital IQ Consensus Estimate. The change in 2012 diluted EPS guidance to $0.10 to $0.20 from $0.56 to $0.66 is due to higher medical costs associated with: 1) an earlier and more intensive flu season in our largest markets; 2) an increase to our previously disclosed premium deficiency reserve for Kentucky; and 3) in Texas, the off-cycle transfer of higher acuity members from another health plan and higher than anticipated utilization in our Hidalgo Star and Medicaid Rural Service Areas business.In regards to the latter, their Texas health plan has been in direct discussions with the State concerning these issues. The company states: "We received a written confirmation acknowledging the issues including the impact 'of the negative effects of one Health Plan's efforts to shift higher acuity membership to its competitors.' The State also confirmed their commitment to rectify the matter as soon as possible. We anticipate any such adjustments will be made in the first quarter of 2013." Additional 2013 guidance assumptions: Consolidated Health Benefits Ratio of ~88.0-89.0%. Consolidated G&A expense ratio in the range of 9.0-9.5%. Effective tax rate, excluding non-controlling interest, of ~40.0-41.0%. Days in claims payable between 39 and 44.
Centene (CNC $43.15 -1.82) issued guidance for fiscal year 2012 with EPS of $0.10-0.20, does not appear comparable to $1.50 Capital IQ consensus, but